SCHEMBL1698111

SCHEMBL1698111

CC(C)(C#N)CC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2443280 0.88 CYP1A2 (0.38)
SCHEMBL14322288 0.79 THRA (0.36)
SCHEMBL1698120 0.77 NSD2 (0.31)
SCHEMBL14152134 0.75
SCHEMBL11389339 0.74
SCHEMBL15693461 0.73 THRA (0.33)
SCHEMBL18567991 0.72 THRA (0.32)
SCHEMBL16823670 0.70
SCHEMBL16823667 0.70
SCHEMBL16830316 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585569-A1 PERFUME SYSTEMS The Procter and Gamble Company (US) 2013-05-01 EP claimed
CN-102947432-A Perfume system PROCTER & GAMBLE 2013-02-27 CN claimed
WO-2011163337-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2011-12-29 WO claimed
US-20110308555-A1 PERFUME SYSTEMS PROCTER & GAMBLE COMPANY, THE 2011-12-22 US claimed
US-20180258371-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-09-13 US disclosed
US-9994793-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2018-06-12 US disclosed
US-9994793-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2018-06-12 US disclosed
EP-3121255-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-03-28 EP disclosed
EP-3121255-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-03-28 EP disclosed
EP-3287511-A1 PERFUME SYSTEMS The Procter & Gamble Company (US) 2018-02-28 EP disclosed
EP-3085759-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-02-07 EP disclosed
CN-107012022-A PERFUME SYSTEMS 宝洁公司 2017-08-04 CN disclosed
US-20080090823-A1 THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. 2008-04-17 US disclosed
US-20070264230-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands SCHERING CORPORATION 2007-11-15 US disclosed
CN-101035768-A Compounds and compositions as cathepsin S inhibitors NOVARTIS AG (CH) 2007-09-12 CN disclosed
EP-1818325-A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION (US) 2007-08-15 EP disclosed
EP-1381590-B1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORP (US) 2007-06-20 EP disclosed
EP-1781623-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS Novartis AG (CH) 2007-05-09 EP disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 US disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed